Nav: Home

Improving the body's ability to fight cancer and intruders

February 07, 2019

The human body's immune system is like a vast team of special agents. Certain cells called T cells each individually specialize in recognizing a particular intruder, such as the influenza virus or salmonella. Determining a given T cell's target is a critical step in designing personalized treatments for cancers and developing vaccines. Now, a team of Caltech scientists has developed two new methods for rapidly determining T cell targets.

The work was done in the laboratory of David Baltimore, Robert Andrews Millikan Professor of Biology and president emeritus. Two papers describing the research appear in the January 28 issue of the journal Nature Methods.

A cell that is infected with a pathogen--for example, an influenza virus--will display bits of the invader's genetic material on the cell surface, like waving a red flag to indicate what is going on inside the cell. These "flags," called antigens, are presented on proteins on the cell surface, called MHCs (major histocompatibility complexes). Each T cell is specialized to recognize a different antigen. When a T cell finds a cell displaying its target antigen on an MHC complex, the T cell will bind to it and destroy it.

There are from 1 million to 5 million unique T cells on average in a human targeting countless different pathogens. Though scientists can characterize the function and molecular makeup of a T cell's receptor, it is difficult to determine what target a given receptor specifically recognizes. In fact, fewer than 1,000 antigen-T cell pairs are known.

Now, led by postdoctoral scholars Alok Joglekar and Guideng Li, researchers in the Baltimore laboratory have developed two new methods for determining the targets of T cells.

In the first method, the scientists attached proteins, called signaling domains, onto MHCs. The new complex, called a signaling and antigen-presenting bifunctional receptor, or SABR, is designed to send a signal into the cell to make it glow bright green once it has been bound by a corresponding T cell. A researcher could then take thousands of different antigens, each presented by a SABR, and combine them with a particular T cell. Only the cells presenting the correct antigen should glow green, allowing the researchers to fish out the correct antigen--the T cell's target.

The second method takes advantage of a natural phenomenon called trogocytosis. This occurs when a T cell and its target cell bind together and exchange proteins that are bound to their surfaces. Although researchers have not yet determined why trogocytosis occurs, the Baltimore laboratory decided to use the phenomenon to indicate T-cell targets. To do this, the researchers made a pool of antigen-presenting cells, each displaying a unique antigen, and then exposed them to T cells with a receptor of interest. Only the cells presenting the correct antigen acquired markers from the T cell via trogocytosis. Afterward, the antigen corresponding to the T cell could then be identified by the marker on its surface.

Understanding antigen-T cell pairs is crucial for developing cancer vaccines and also for designing personalized treatments for cancers, as antigens can also be signatures of cancer. No two cancers are the same, and because cancer cells grow so rapidly, they also mutate rapidly. Ideally, then, a scientist could take a sample of a person's tumors, isolate T cells from them, and use one of these methods to discover the antigens that are targeted by the T cells. Once these targets are identified, the T cells can be used to augment the patient's own immune system in various ways to help it better fight the person's cancer.
A paper describing the SABR method is titled "T cell antigen discovery via Signaling and Antigen presenting Bifunctional Receptors." Postdoctoral scholar Alok Joglekar is the study's first author. In addition to Joglekar and Baltimore, co-authors are Caltech research technicians Michael Leonard and Margaret Swift; former Caltech research technician John Jeppson; postdoctoral scholar Guideng Li; former Caltech undergraduate and current research technician Stephanie Wong (BS '16); former Caltech postdoctoral scholar Songming Peng now of PACT Pharma; Jesse Zaretsky of UCLA; James Heath, a former Caltech professor now at the Institute for Systems Biology in Seattle; Antoni Ribas of UCLA; and former postdoctoral scholar Michael Bethune.

A paper describing the trogocytosis method is titled "T cell antigen discovery via trogocytosis." Guideng Li and Michael Bethune are the study's first authors. In addition to Li, Bethune, and Baltimore, co-authors are Stephanie Wong; Alok Joglekar; Michael Leonard; undergraduate Jessica Wang; former graduate student Jocelyn Kim (PhD '16), now of UCLA; Donghui Cheng of UCLA; Songming Peng; Jesse Zaretsky; Caltech graduate students Yapeng Su and Yicheng Luo; James Heath; Antoni Ribas; and Owen Witte of UCLA. Baltimore, Ribas, Heath, and Witte are also members of the Parker Institute for Cancer Immunotherapy at UCLA and Caltech.

California Institute of Technology

Related Cancer Articles:

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
More Cancer News and Cancer Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Why do we revere risk-takers, even when their actions terrify us? Why are some better at taking risks than others? This hour, TED speakers explore the alluring, dangerous, and calculated sides of risk. Guests include professional rock climber Alex Honnold, economist Mariana Mazzucato, psychology researcher Kashfia Rahman, structural engineer and bridge designer Ian Firth, and risk intelligence expert Dylan Evans.
Now Playing: Science for the People

#540 Specialize? Or Generalize?
Ever been called a "jack of all trades, master of none"? The world loves to elevate specialists, people who drill deep into a single topic. Those people are great. But there's a place for generalists too, argues David Epstein. Jacks of all trades are often more successful than specialists. And he's got science to back it up. We talk with Epstein about his latest book, "Range: Why Generalists Triumph in a Specialized World".
Now Playing: Radiolab

Dolly Parton's America: Neon Moss
Today on Radiolab, we're bringing you the fourth episode of Jad's special series, Dolly Parton's America. In this episode, Jad goes back up the mountain to visit Dolly's actual Tennessee mountain home, where she tells stories about her first trips out of the holler. Back on the mountaintop, standing under the rain by the Little Pigeon River, the trip triggers memories of Jad's first visit to his father's childhood home, and opens the gateway to dizzying stories of music and migration. Support Radiolab today at